Introduction: The authors describe the medications for treatment-resistant depression (TRD)
in phase II/III of clinical development in the EU and USA and provide an opinion on how …

Patients with major depressive disorder (MDD) often exhibit an inadequate treatment
response or failure to achieve remission following treatment with antidepressant drugs …

Importance of the field: Treatment-resistant depression (TRD) is common and debilitating.
Initial treatment is often insufficient to achieve full remission in a given depressive episode …

A significant proportion of patients with major depressive disorder (MDD) fail to achieve
remission with standard antidepressant therapies, even when optimally delivered. These …

AIM: To review evidence supporting pharmacological treatments for treatment-resistant
depression (TRD) and to discuss them according to personal clinical experience …

Treatment-resistant depression (TRD) presents many challenges for both patients and
physicians. This review aims to evaluate the current status of the field of TRD and reflects the …

One in three adults with major depressive disorder (MDD) do not experience clinically
significant improvement after multiple sequential courses of antidepressants and have …

Abstract Purpose of Review We review recent advances in the treatment of treatment-
resistant depression (TRD), a disorder with very limited treatment options until recently. We …

Major depressive disorder (MDD) is associated with a significant burden and costs to the
society. As remission of depressive symptoms is achieved in only one-third of the MDD …

Major depressive disorder (MDD) is a leading cause of disability worldwide. Current first line
therapies target modulation of the monoamine system. A large variety of agents are currently …